All In Biotech

Drug Trial Radar · NCT07712705

HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oral HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 515 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

515

Actual

Start

Apr 20, 2023

Primary completion

Sep 29, 2023

Study completion Feb 20, 2025

Sponsor

Lead sponsor
Newsoara Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to a placebo at Week 16, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. Participants will: Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) Eligible participants are adults aged 18 years and older with a confirmed diagnosis of chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.

Conditions

  • Psoriasis

Interventions

  • HPP737Drug

    HPP737 capsule for oral administration

  • Placebo matching HPP737Drug

    Placebo capsules matching HPP737 for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 16Time frame: From enrollment to end of treatment at 16 weeks

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Cangzhou People's Hospital

    Cangzhou, China

  • The Second Hospital of Jilin University

    Changchun, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Xiangya Hospital, Central South University

    Changsha, China

  • Affiliated Hospital of Chengde Medical College

    Chengde, China

  • Chengdu Second People's Hospital

    Chengdu, China

  • Dongguan First People's Hospital

    Dongguan, China

  • Shengli Oilfield Central Hospital

    Dongying, China

  • The First Affiliated Hospital of Gannan Medical University

    Gannan, China

  • Dermatology Hospital, Southern Medical University

    Guangzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, China

  • Shandong Provincial Hospital of Dermatology

    Guiyang, China

  • Hangzhou First People's Hospital

    Hangzhou, China

  • Hangzhou Third People's Hospital

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, China

  • Jiaxing First Hospital

    Jiaxing, China

  • Jinan Central Hospital

    Jinan, China

  • Shandong Provincial Hospital of Dermatology

    Jinan, China

  • Shandong Provincial Hospital

    Jinan, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, China

  • The First People's Hospital of Lianyungang

    Lianyungang, China

  • Jiangxi Provincial Dermatology Hospital

    Nanchang, China

  • Nanyang Central Hospital

    Nanyang, China

  • Nanyang First People's Hospital

    Nanyang, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM

    Shanghai, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, China

  • Shiyan People's Hospital

    Shiyan, China

  • Suining Central Hospital

    Suining, China

  • Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine

    Tianjin, China

  • Wuhan First Hospital

    Wuhan, China

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.